Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b…
Dec 20, 2022 · 16 th patient dosed with IMX-110 to date; This is the second patient dosed with IMX-110 in December 2022; Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical data expected to …
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX ...
Jan 13, 2023 · IMX-110 clinical trial data is expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110. “We are delighted with continued robust IMX-110 clinical trial enrollment,” said Ilya Rachman, MD PhD, CEO of ImmixBio.
IMX-110/Tislelizumab Yields Notable Tumor Shrinkage in Two …
May 5, 2023 · Investigational agent IMX-110 plus tislelizumab resulted in tumor shrinkage at 2 months in patients with advanced metastatic colorectal cancer (CRC), according to a press release on interim data from the phase 1b/2a IMMINENT-01 trial.
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim …
Jan 19, 2022 · Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation (RPDD) for the treatment of rhabdomyosarcoma, a life-threatening form of …
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX ...
Jan 13, 2023 · IMX-110 is currently being evaluated in a phase 1b/2a clinical trial in patients with advanced solid tumors. Learn more at www.immixbio.com/iMX-110 About Immix Biopharma, Inc.
Immix Biopharma Announces Dosing of First 2 Patients in its
Feb 7, 2023 · IMX-110 + Beigene/Novartis anti-PD-1 tislelizumab combination treatment is designed to enhance response to solid tumors by turning immunologically “cold” tumors “hot”.
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX …
Immix Biopharma, Inc, a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced patient dosing in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. This is the fifteenth patient dosed with IMX-110 to-date.
Immix Biopharma Announces Dosing of First 2 Patients in its IMX …
Feb 7, 2023 · Immix Biopharma, Inc. today announced dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab Combination Phase 1b/2a Clinical Trial in patients with advanced solid tumors.
IMX-110 Granted Rare Pediatric Disease Designation by FDA …
Jan 5, 2022 · The FDA has granted a rare pediatric disease designation to IMX-110, qualifying the treatment to receive priority review and a fast track designation voucher, for pediatric patients with life threatening rhabdomyosarcoma. 1. The therapy is currently being assessed as part of an ongoing phase 1b/2a study (NCT03382340).
Immix Biopharma Announces Early Positive IMX-110 Interim …
May 3, 2023 · Dosing of the first cohort of three advanced metastatic colorectal cancer patients is complete, as of April 14, 2023, for the ongoing Phase 1b portion of the IMMINENT-01 Phase 1b/2a...